Document is current
Any future updates will be listed below
-
Authors
Trecourt, Alexis https://orcid.org/0000-0002-1674-1888
Valent, Alexander
Yaniz-Galende, Elisa
Rouleau, Etienne
Grau Bejar, Juan Francisco
Blanc-Durand, Félix https://orcid.org/0000-0002-5277-1515
Edmond, Elodie
Le Formal, Audrey
Genestie, Catherine
Leary, Alexandra
-
Funding
Funding for this research was provided by:
Parrainage Tumeurs gynécologiques of Gustave Roussy.
Cancéropôle Lyon Auvergne-Rhône-Alpes (CLARA).
- License Information
-
More Information
Article History
Received: 6 August 2025
Revised: 17 December 2025
Accepted: 30 March 2026
First Online: 5 May 2026
Competing interests
: Alexandra Leary reports a relationship with Zentalis, Daiichi, AZ for funding grants. Alexandra Leary reports a relationship with AstraZeneca, MSD, GSK, Abbvie that includes: consulting or advisory and travel reimbursement. AL reports a relationship with Eisai, Regeneron, Zentalis, Pharm&, Apmonia, Owkin for consulting or advisory boards. All fees provided to institution not self. Etienne Rouleau reports a relationship with AstraZeneca, MSD, GSK, Roche, BMS, Clovis, Pharmaand for consulting and advisory board. The other authors declare no potential conflicts of interest.
: Informed consents were obtained for all patients included in the present study. The FFPE samples from patients included in herein have been declared to the French Ministry of Research ( Gustave Roussy authorisation number: DC-2020-4158). The present study was approved by the local ethics committee (no. 2025–504) and was conducted in accordance with the Declaration of Helsinki.
